However, when considering CD8A and PDL1 expression (a surrogate for tumour immunogenicity), almost 50% of cutaneous melanomas are considered CD8Ahigh/PDL1high, whereas the same percentage of UM are considered CD8Alow/PDL1low, reflecting a more immunosuppressed tumour microenvironment (Figure 4A,B). The gene discussed is CD8A; the disease is neoplasm.